Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ACIU
#6082
AC Immune SA
2.9
3
-0.34%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-0.34%
Monthly Change
-17.93%
6 month change
+42.23%
Cambio anual
+14.45%
Cierres anteriores
2.9
4
Open
2.9
3
Bid
Ask
Low
2.9
3
High
2.9
3
Volumen
17
Markets
Acciones
Atención Sanitaria
ACIU
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
71.94 M
83.48 M
83.62 M
99.2 M
100.41 M
366.71 M
Valuation ratios
Enterprise value
371.91 M
413.22 M
184.8 M
465.24 M
271.11 M
1.33 B
Price to earnings ratio
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
Noticias
AC Immune inicia ensayo de fase 1 de inhibidor NLRP3 penetrante cerebral
AC Immune inicia ensayo fase 1 de inhibidor NLRP3 que penetra cerebro
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
Tesla and Rivian among market cap stock movers on Friday
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - AC Immune (NASDAQ:ACIU)
Las acciones de AC Immune suben tras datos positivos de ensayo para Parkinson
Acciones de AC Immune suben tras datos positivos en ensayo de Parkinson
AC Immune stock rises after positive Parkinson’s disease trial data
El tratamiento para el Parkinson de AC Immune muestra promesas en frenar la enfermedad
Tratamiento de AC Immune para Parkinson muestra promesa en frenar la enfermedad